AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
Wednesday, March 15, 2023
AcelRx Pharmaceuticals announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora). The agreement allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialisation of DSUVIA.
The agreement with Alora Pharmaceuticals provides AcelRx with 15 percent royalties on commercial sales, 75 percent royalties on Department of Defence (DoD) sales, up to $116.5 million in potential sales-based milestone payments, and a strong commercial partner experienced with commercialisation in hospital settings.
This partnership enables to continue the growth and distribution of DSUVIA to ensure access by patients. This product will help Alora Pharmaceuticals expand pain management portfolio. DSUVIA provides an effective solution for patients in a certified medically supervised healthcare setting, such as hospitals, surgical centres, and emergency departments, with management of acute pain severe enough to require an opioid analgesic.
The divestment of DSUVIA marks a new chapter in the evolution of AcelRx, allowing it to laser-focus on the development of valuable late-stage development assets led by Niyadi. The divestment of DSUVIA, plus the advancement of both nafamostat and pre-filled syringe portfolio programmes, builds long-term value for shareholders and sets on the path to a new era for the Company with multiple late-stage, and potentially commercial stage assets within the next 12 months.
